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Myofibroblasts are matrix-producing cells with contractile properties, usually
characterized by de novo expression of alpha-smooth muscle actin, that arise in
fibrotic diseases. Hepatic stellate cells (HSCs), known as perisinusoidal cells containing
auto-fluorescent vitamin A, are the major although not exclusive source of myofibroblasts
in the injured liver. Portal myofibroblasts (PMFs) have been defined as liver myofibroblasts
derived from cells that are distinct from HSCs and located in the portal tract. Here,
we describe the protocol we have established to obtain rat PMFs in culture. In this
method, the biliary tree is (i) separated from the liver parenchyma by in situ enzymatic
perfusion of the liver, (ii) minced and further digested in vitro, until bile duct segments
are isolated by sequential filtration. Bile duct isolates free of HSC contaminants, form
small cell clusters, which initially comprise a large majority of epithelial cells. In culture
conditions (fetal bovine serum) that provide a growth advantage to mesenchymal
cells over epithelial cells, the epithelial cells die and detach from the substrate, while
spindle-shaped cells outgrow from the periphery of the cell clusters, as shown by
video-microscopy. These cells are highly proliferative and after 4–5 days, the culture is
composed exclusively of fully differentiated myofibroblasts, which express alpha-smooth
muscle actin and collagen 1, and secrete abundant collagen. We found no evidence for
epithelial-mesenchymal transition, i.e., no co-expression of alpha-smooth muscle actin
and cytokeratin at any stage, while cytokeratin becomes undetectable in the confluent
cells. PMFs obtained by this method express the genes that were previously reported
to be overexpressed in non-HSC or portal fibroblast-derived liver myofibroblasts as
compared to HSC-derived myofibroblasts, including the most discriminant, collagen 15,
fibulin 2, and Thy-1. After one passage, PMFs retain the same phenotypic features as
in primary culture. In conclusion, this straightforward and reproducible method of PMF
culture, can be used to identify new markers of PMFs at different stages of differentiation,
to compare their phenotype with those of HSC-MFs and ultimately determine their
progenitors and specific functions in liver wound-healing.
Keywords: alpha-smooth muscle actin, bile ducts, collagen-type XV-alpha 1, cytokeratin 19, fibulin 2, liver fibrosis,
liver digestion, portal tract
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INTRODUCTION
Myofibroblasts are cells that arise in fibrotic diseases. They are
matrix-producing cells with contractile properties, characterized
by de novo expression of proteins shared with smooth muscle
cells. Myofibroblasts form a heterogeneous population of cells
with different possible origins. Alpha-smooth muscle actin (α-
SMA) is their most commonly used marker (Hinz et al., 2012).
Hepatic stellate cells (HSCs) have been identified as the major
source of myofibroblasts in the injured liver (Friedman, 2008),
in particular by studies of cell lineage tracing (Mederacke et al.,
2013). HSCs are recognized in their quiescent state, as vitamin
A-storing cells located in the perisinusoidal space of Disse.
However, culture studies and in situ studies of fibrotic livers have
provided evidence to indicate that liver myofibroblasts could
also derive from cells that are distinct from HSCs and located
in the portal area (Cassiman et al., 2002; Uchio et al., 2002;
Kinnman et al., 2003; Beaussier et al., 2007; Li et al., 2007).
Today, we refer to this sub-population of liver myofibroblasts as
portal myofibroblasts (PMFs) (Lemoinne et al., 2013). Cells called
portal fibroblasts have also been described. They are periductal
α-SMA-negative fibroblastic cells found in the normal liver,
that express ecto-nucleoside triphosphate diphosphohydrolase 2
(ENTPD2) (Tuchweber et al., 1996; Dranoff et al., 2002). There is
evidence to indicate that portal fibroblasts can become activated,
i.e., myofibroblastic, in biliary-type liver fibrosis. However, this
does not mean that PMFs all derive from portal fibroblasts. In
fact, the progenitor cells of PMFs have not been identified yet.
To a large extent, our knowledge regarding PMFs is based on
a rat culture model that we previously established (Kinnman
et al., 2003; Bosselut et al., 2010). In this model, PMFs are
obtained by outgrowth from bile duct preparations. We showed
that PMFs obtained by this method expressed a number of
genes at higher levels than HSC-derived myofibroblasts (HSC-
MFs) (Lemoinne et al., 2015). This included fibulin 2 and
other genes such as Thy-1, gremlin 1, and fibronectin 1
that were also found by others to be overexpressed in non-
HSC derived liver myofibroblasts as compared to HSC-MFs
(Knittel et al., 1999; Ogawa et al., 2007; Dudas et al., 2009).
This also included the most discriminant marker of non-
HSC derived myofibroblasts identified so far, with the highest
expression ratio relative to HSC-MFs, i.e., collagen-type XV-
alpha 1 (COL15A1).
Non-HSC derived liver myofibroblasts were previously
obtained in culture, by different methods of cell isolation. The
so-called rat liver myofibroblasts were isolated by enzymatic
digestion of the liver, followed by separation of non-parenchymal
cells by density gradient and purification of a fraction enriched
in myofibroblast precursors by elutriation (Knittel et al.,
1999). Vitamin A-free cells were also isolated from a stellate
cell-enriched fraction of normal rat liver by fluorescence-
activated cell sorting (FACS) (Ogawa et al., 2007). Cells
Abbreviations: α-SMA, alpha-smooth muscle actin; CK, cytokeratin; COL,
collagen; D, day; ENTPD2, ectonucleoside triphosphate diphosphohydrolase-2; H,
hour; Hep, hepatocyte; HPRT, hypoxanthine guanine phosphoribosyl transferase;
HSC, Hepatic stellate cell; NS, not significant; PMF, portal myofibroblast.
that were negative for ultraviolet-autofluorescence of vitamin
A were thus obtained by FACS and formed myofibroblasts
in culture, with distinctive features compared to HSC-MFs.
Another method has been described (Kruglov et al., 2002)
and subsequently modified (Wen et al., 2012), to isolate cells
assumed to be portal fibroblasts, from rat liver. First, the
biliary tree is prepared by enzymatic digestion of the liver
and isolated cells presumably enriched in portal fibroblasts,
obtained by size-based filtration. Two markers of portal
fibroblasts have been reported, ENTPD2, which is lost after
myofibroblastic differentiation in culture, and elastin, which is
maintained.
None of these methods, has yet allowed to clearly identify
the progenitor cells distinct from HSCs that contribute to liver
myofibroblasts, their fate and functions, compared to those of
HSC-MFs in liver tissue repair. The advantage of our model
is that (i) the outgrowth of myofibroblasts reproduces the
pattern of fibrosis progression from the portal area toward
the lobule observed in vivo; (ii) portal progenitors are not
dissociated from their initial niche, avoiding cell selections; (iii)
the protocol, phenotype and markers of myofibroblasts obtained
by this method, are all very reproducible. The limitations are the
abundance of contaminant bile duct epithelial cells in the initial
preparation, and possibly, a diversity of myofibroblast progenitor
cells. This protocol can be used to identify new markers of PMFs
at different stages of differentiation, to compare the behavior and
functions of these cells with those of HSC-MFs and determine
their interactions with HSC-MFs.
MATERIALS AND EQUIPMENT
N.B. European catalog numbers (Cat. No.) are provided.
Animals
Sprague Dawley rats weighing 150–200 g (Janvier Labs). Different
strains (e.g., Wistar) can be used. The protocol is optimal when
rats body weight is ≤250 g. Animals were housed under specific
pathogen free conditions (PHEA, agreement No: B 75-12-01).
Enzymes/Chemicals
- Betadin
R©
- Bovine serum albumin (BSA, Sigma-Aldrich Cat. No. A7030)
- Collagenase P (Sigma-Aldrich Cat. No. 11 213 873 001)
- DNAse (Sigma-Aldrich Cat. No. DN25> 400 units/mg)
- EDTA 0.5 mol/L pH 8.0 (Sigma-Aldrich Cat. No. 03690)
- Hyaluronidase (Sigma-Aldrich Cat. No. H3884 type IV-S750
3000 units/mg)
- Pronase (Roche Cat. No. 11 459 643 001)
- Sodium heparin (5000 IU/ml)
- Sodium pentobarbital (CEVA animal healthy 5.47 g/100 ml)
Culture Media
- DMEM (Sigma-Aldrich Cat. No. D6046)
- Fetal Bovine Serum (FBS, GIBCO Invitrogen Cat. No. 10270-
098)
- HBSS with MgCl2 and CaCl2 (GIBCO Invitrogen Cat. No.
24020-022)
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- HBSS without MgCl2 or CaCl2 (GIBCO Invitrogen Cat. No.
14170-088)
- Hepes (GIBCO Invitrogen Cat. No. 15630)
- L15 Leibovitz medium (Sigma-Aldrich Cat. No. L5520)
- MEM with Earl’s without glutamin (GIBCO Invitrogen Cat.
No. 21090-022)
- NaCl solution (9 g/L) (OTEC Cat. No. 600502)
- Penicillin/streptomycin (GIBCO Invitrogen Cat. No. 15140-
122)
Equipment
- 12-well plates
- 16 gauge X 50 mm IV catheter (Jelco Cat. No. 4012)
- Bottle-top filter 0.22µm (Thermo scientific Cat. No. 568-0020)
- Bubble trap (Medi-Globe Cat. No. 200927)
- Cell strainer 40 and 100 µm Nylon (Falcon Cat. Nos. 352340
and 352360)
- Cotton and linen threads
- Falcon tubes 50 mL
- Glass beakers 250 mL
- Heat lamp
- Orbital water bath
- Perfusion line (Masterflex Cat. No. 96410-16)
- Perfusion pump (Masterflex Cat. No. 751800)
- Plate with magnetic stirrer
- Refrigerated (+4◦C) bench-top centrifuge
- Schott Pyrex bottles 150, 250, and 500 mL
- Sterile filter for syringe (0.22 µm)
- Sterile Petri dishes
- Sterile pipettes 5, 10, 25 mL
- Sterilized fork and scissors
- Syringes 3 and 50 mL
- Water bath
Reagent Set-Up
• Dilute pentobarbital at 1/10 in NaCl solution.
• EDTA solution (19 mg/L): Prepare the solution by dissolving
6.5mL EDTA in 43.5mL sterile water and filter through a 0.22-
µm syringe filter. This solution can be prepared up to 4 weeks
in advance and stored at+4◦C.
• L15 1% Hepes solution: Under sterile condition, dilute 5 mL
Hepes (1 mol/L) in 500 mL L15 medium.
• Wash solution (HBSS without MgCl2 or CaCl2, 1% EDTA):
Dilute 2 mL of 19-mg/L EDTA solution in 200 mL HBSS
without CaCl2 or MgCl2. Adjust the pH to 7.35–7.40 and filter
it through 0.22-µm bottle-top filter.
• Enzyme solution 1: Add 15 mg collagenase P in 200 mL HBSS
with MgCl2 and CaCl2. Place the mixture on a magnetic
shaker until dissolution and adjust the pH to 7.35–7.40 and
filter it through 0.22-µm bottle-top filter.
• Enzyme solution 2. In 200 mL MEM, dissolve 15 mg
collagenase P, 140 mg pronase, 13 mg DNAse and 200 mg
BSA. Supplement with 1% penicillin/streptomycin, 1% Hepes
and 3% FBS. Place the mixture on a magnetic shaker until
dissolution, adjust the pH to 7.35–7.40 and filter it through
0.22-µm bottle-top filter.
• Enzyme solution 3. In 100mLMEM, dissolve 6mg collagenase
P, 20 mg hyaluronidase, 6 mg DNAse and 100 mg BSA.
Supplement with 1% penicillin/streptomycin, 1% Hepes and
3% FBS. Place the mixture on a magnetic shaker until
dissolution, adjust the pH to 7.35–7.40 and filter it through
0.22-µm bottle-top filter.
• Complete DMEM: Supplement DMEM with 1%
penicillin/streptomycin, 1% Hepes and 10% FBS.
N CRITICALWash and enzyme solutions should be prepared
no later than 18 h before starting the isolation procedure.
Equipment Set-Up
Fill perfusion line and bubble trap with wash solution and adjust
the flow rate of perfusion pump at 10 mL/min.
PROCEDURE
Procedure Set-Up (60 min)
Described in Section Reagent Set-Up and Equipment Set-Up.
N CRITICALWash solution and enzyme solution 1 should be
preheated in the water bath (38◦C).
In situ Digestion of Rat Liver (90 min)
1- Anesthetize the rat according to the institutional approved
animal protocol. We perform pentobarbital intra-peritoneal
injection (1 mL/100 g body weight).
2- Shave the abdomen and clean with Betadin
R©
.
3- Immobilize the rat by the upper and lower extremities on a
dissecting board.
4- Perform a laparatomy to expose the liver, and move the
visceral organs to the right side to expose the inferior vena
cava and the portal vein.
5- Ligate the gastro-duodenal vein with a cotton thread. Then,
prepare two linen threads around the portal vein under the
gastro-duodenal vein, not to ligate at this stage. Prepare also
a linen thread around the infrahepatic vena cava above the
renal vein, not to ligate at this stage.
6- Inject 500 IU heparin in the femoral vein.
7- Place a 16-gauge catheter into the portal vein, entering under
the gastro-duodenal vein. Check the position of the catheter
that should not point upward in the vein, and ligate the two
linen threads around the catheter placed in the portal vein. !
Troubleshooting (Table 1).
8- Start the pump, connect the catheter to the perfusion line
and stabilize the set-up to avoid exit of the catheter. N
CRITICAL STEP Before connecting the perfusion line, make
certain that no bubbles are introduced in the catheter, which
would result in improper digestion.
9- Section the infrahepatic vena cava beneath the unligated
linen thread that was prepared in step 5.
10- Place a 16-gauge catheter through the right auricle into the
suprahepatic vena cava and fix it with a linen thread.
11- Ligate the infrahepatic vena cava by using the linen thread
that was prepared in step 5. Thereafter, perfused solutions
will outflow through the auricle catheter (Figure 1A).
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TABLE 1 | Troubleshooting.
Step Problem Possible reason Solution
7 Catheter exit from the portal vein Abrupt manipulation Inverse perfusion direction by placing the catheter in the right auricle and use it for perfusion;
linen threads around the portal vein are removed to allow outflow
14 Catheter exit from the explanted liver Abrupt manipulation Inject L15 medium through the liver capsule using a syringe
23 Tan color of hepatocytes visible in
preparations remaining on the 40-µm
cell strainer
Contamination
during filtration steps
Increase the number of filtration through 40-µm cell strainers
25 Low purity (contaminating
hepatocytes)
Incomplete digestion Make sure that the enzyme concentrations are correct
Make sure that all liver lobules are perfused
12- Perfuse the liver with wash solution for a total of 20 min.
Switch on the heat lamp directed toward the rat liver to
maintain a temperature of 37◦C and hydrate the liver with
NaCl solution during perfusion. N CRITICAL STEP Make
sure that all liver lobules are perfused. If it was not the case,
you can gently move the catheter.
13- Switch from wash solution to enzyme solution 1
and perfuse the liver for 15–20 min, until digestion
becomes visible.
14- Disconnect the perfusion line from the catheter but do not
remove the intra-portal catheter from the liver. Explant the
liver and place it in a sterile 100-mm Petri dish. Inject 20 mL
of cold L15 medium (+4◦C) with a syringe through catheter
to dislocate hepatocytes, and repeat this injection twice. !
Troubleshooting (Table 1).
15- Under cell culture hood, transfer the liver to a new sterile
100-mm Petri dish with L15 medium at room temperature.
Peel off the liver capsule and detach the liver parenchyma
by scrubbing with a fork, until the biliary tree is isolated
(Figure 1B).
In vitro Biliary Tree Digestion (150min)
N CRITICAL Enzyme solutions 2 and 3 should be preheated in
the water bath (38◦C).
16- Transfer the biliary tree to a 100-mm sterile Petri dish
containing pre-warmed enzyme solution 2. Cut the biliary
tree into small pieces with scissors and transfer the minced
biliary tree into a 250-mL Schott Pyrex bottle. Add enzyme
solution 2 to a final volume of 100 mL and place the bottle
in an orbital water bath at 37◦C. Shake the bottle during 30
min. N CRITICAL STEP The result of mincing should be a
homogeneous preparation of very small fragments.
17- Filter this preparation through a 100-µm cell strainer and
then through a 40-µm cell strainer. Discard the filtrate from
the 40-µm cell strainer.
18- Suspend the preparations remaining on the 100-µm and 40-
µm cell strainers in 100 mL of enzyme solution 2. Place the
mixture under shaking at 37◦C, for 30 min. N CRITICAL
STEP Increase the digestion time if chunks are visible.
19- Repeat step 17.
20- Suspend the preparations remaining on the 100 and 40-µm
cell strainers in 100 mL of enzyme solution 3. Place the
mixture under shaking at 37◦C for 30 min. N CRITICAL
FIGURE 1 | Enzymatic digestion of the liver. (A) Set-up for in situ liver
perfusion. A catheter is inserted into the portal vein (blue threads) and
connected to the perfusion tubing. After starting the perfusion, the vena cava
is sectioned under the liver to prevent hyper-pressure in the liver. Then, a
catheter is inserted through the right auricle into the inferior vena cava (pink
thread) to drain the outflow from the liver, and the thread (green) around the
vena cava, just above section, is ligated. (B) Biliary tree isolated by in situ
digestion, placed in a 100-mm culture dish. (C) Bile duct isolates obtained
immediately after in vitro digestion of the biliary tree (a,a’), in comparison with
freshly isolated HSCs (b,b’), under phase-contrast microscopy (a,b) or
epifluorescence microscopy at 328-nm UV excitation (a’,b’), form small cell
clusters free of autofluorescent HSCs.
STEP Exceeding 40 min of incubation may result in a poor
yield of bile duct segments.
21- Filter the mixture through a 100-µm cell strainer and collect
the filtrate for two additional filtrations, each time with a
new 100-µm cell strainer.
22- Subject the filtrate obtained in step 21 to filtration through a
40-µm cell strainer. Discard the filtrate.
23- Suspend the preparation remaining on the 40-µm cell
strainer in L15 medium. Proceed to a last filtration
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through a 40-µm cell strainer and discard the filtrate. !
Troubleshooting (Table 1).
24- Suspend the preparation remaining on the 40-µm cell
strainer in 50 mL complete DMEM and transfer it into a
50-mL Falcon tube.
Cell Culture
25- Centrifuge at 1900 rpm during 8 min at room temperature.
Discard the supernatant. Suspend the cell pellet in complete
DMEM and plate the cells in 12-well culture dishes (1
mL/well). The yield of cell clusters is 7000–10,000 per rat
liver. N CRITICAL STEP The volume of complete DMEM
should be adapted to the size of the cell pellet so as to obtain
four to six cell clusters per microscope field at magnification
x10. Perform microscope observation under 328-nm UV
excitation to exclude contamination by HSCs (Figure 1C).
! Troubleshooting (Table 1).
26- Maintain cell culture at 37◦C in a 5%CO2 incubator. Replace
the culture medium 24 h after seeding and every 48 h,
thereafter. Generally, cells are confluent after 4–5 days in
primary culture, a stage we refer to as passage 0 (P0).
27- Confluent cells can undergo several passages. They are fully
differentiated in myofibroblasts, in primary culture (P0) and
after one passage (P1).
RESULTS
Methods Used to Characterize PMF
Culture
RT-PCR
Total RNA was used to prepare cDNA. Quantitative real-
time PCR was performed using Sybr Green Master Mix on
a Lightcycler 96 (Roche). Target gene mRNA levels were
reported relative to a calibrator according to the 2−11Ct method
with hypoxanthine guanine phosphoribosyl transferase (Hprt)
used as the reference gene. Primer sequences are provided in
Supplementary Table 1.
Fluorescence
To monitor cell viability in culture, NucGreen
R©
Dead
488 reagent (ThermoFisher) was added to the culture
medium, following the manufacturer’s instructions. For
immunofluorescence, cell preparations were fixed in 4%
paraformaldehyde for 15 min, then blocked and permeabilized,
by incubation in 2% albumin (Roche) supplemented with
0.1% Triton X100 (Sigma-Aldrich) for 1 h. Fixed cells were
incubated with the primary antibodies against: COL15A1
(HPA017913, 1/30, Sigma-Aldrich), α-SMA (1A4, 1/100, Dako),
or pan-cytokeratin (sc-8018, 1/10, Santa Cruz Biotechnology)
overnight at 4◦C. Primary antibody was revealed by Alexa Fluor
488 or 568-conjugated antibodies (1/200, Life Technologies) and
DAPI was used for nuclear staining. For dual α-SMA and pan-
cytokeratin immunofluorescence, Alexa Fluor 488-conjugated
α-SMA (1/100, Abcam) and Alexa Fluor 647-conjugated
pan-CK (1/10, Cell Signaling) antibodies were used. Image
acquisition was performed, using a SP8 confocal microscope
(Leica). For proliferation assay, fixed cells were incubated
with the Alexa Fluor 488-conjugated Ki67 antibody (1/50, Cell
Signaling) overnight at +4◦C and DAPI was used for nuclear
staining. Ki67-positive cells was counted in 5 random fields at
magnification x20 using ImageJ software and reported to the
total cell numbers (%).
Collagen Assay
Conditioned medium prepared from cells incubated with or
without 10% FBS for the last 24 h, was analyzed for soluble
collagen using the Sircol collagen assay, according to the
manufacturer (Sigma-Aldrich). Briefly, Sircol reagent was added
to the conditioned medium to form collagen-dye complex.
FIGURE 2 | PMF outgrowth in culture. PMF culture in complete medium
(i.e., supplemented with 10% FBS), containing NucGreen
®
Dead reagent to
monitor cell death, was observed by Video-Microscopy (Supplementary
Video). Phase-contrast, fluorescent and merge images at different time points
are shown. H, hours; Scale bars, 50 µm.
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The precipitates were collected by centrifugation, dissolved in
0.5 mol/L NaOH and dye concentration was estimated by
spectrophotometry at 540 nm.
PMF Culture Characterization
In the culture model of PMFs presented here, myofibroblasts
are obtained by outgrowth from bile duct preparations. These
preparations form small cell clusters that are entirely free of
HSC contamination, as ascertained by the absence of vitamin A
autofluorescence (Figure 1C). They initially contain a majority
of bile duct epithelial cells as shown by cytokeratin staining
(Figure 3Ba), and trace amounts of vascular structures as shown
by α-SMA staining detectable in approximately one bile duct
segment out of five (data not shown). They are placed in culture
conditions with FBS, which contains factors such as TGF-β,
that provide a growth advantage to mesenchymal cells over
epithelial cells, in primary culture. In these conditions, bile duct
epithelial cells die and detach from the substrate, while cells
with a spindle-shape morphology, outgrow from the cell clusters.
The time course of this evolution in culture can be observed
by Video-Microscopy (Supplementary Video). Morphology of
the cells observed under video-microscopy at different time
points of culture, is shown in Figure 2. The time course of gene
expression assessed by RT-PCR in the cultured cells (Figure 3A),
FIGURE 3 | Time course of cell markers in PMF culture. PMF culture was subjected at different time points, to (A) RT-PCR analysis of cytokeratin 19 (CK19),
ecto-nucleoside triphosphate diphosphohydrolase 2 (Entpd2), Vimentin, Acta2/α-SMA, Col1a1, Col15a1, Fibulin 2, and CD90/Thy-1; mRNA levels are normalized for
Hprt and reported relative to those measured immediately after bile duct isolation (D0). They represent the means ± standard error of 2–3 preparations. (B)
Immunofluorescence of cytokeratin (CK), and of α-SMA co-labeled with CK or COL15A1; nuclei were stained with DAPI; z images at 5.7 (Z04) and 13.6 (Z27) µm from
the substrate are shown. D, days; Scale bars, 50 µm.
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shows that the expression of cytokeratin 19 (CK19) used as a
marker of bile duct epithelial cells, progressively decreases over
time, to become virtually absent at the stage of confluence,
after 4 days in culture. The expression of Entpd2, previously
shown to be a marker of portal fibroblasts and to undergo
down-regulation during the myofibroblastic differentiation of
these cells (Dranoff et al., 2002; Li et al., 2007; Wen et al.,
2012), increases at day 1, when the fibroblastic cells emerge
and decline thereafter. The expressions of Vimentin, a general
marker of mesenchymal cells, and of Acta2/α-SMA, a marker of
myofibroblasts, progressively increase after day 2. The expression
of collagen, type I, alpha 1 (Col1a1) increases after day 3,
whereas expressions of the PMF markers Col15a1, Fibulin 2,
and CD90/Thy-1, are induced at the stage of confluence, after
4 days. We also found that the expression of elastin, a marker
of portal fibroblasts, could be detected in bile duct isolates
FIGURE 4 | Phenotype of PMFs in culture. Characterization of PMFs at confluence in primary culture (P0) and after one passage (P1), by (A) RT-PCR analysis of
Vimentin, Acta2/α-SMA, Col1a1, Col15a1, Fibulin 2, and CD90/Thy-1; mRNA levels are normalized for Hprt and reported relative to those measured at P0. They
represent the means ± standard error of 7 preparations. (B) Collagen secretion, measured in the conditioned media of PMFs (n = 3–9) or hepatocytes (Hep, n = 1),
used as controls, incubated with or without 10% FBS for the last 24 h; Results are normalized for total protein amount and represent the means ± standard error.
(C) Proliferation assay by Ki67 immunofluorescence, in sub-confluent PMFs incubated with or without 10% FBS for the last 24 h; results are expressed as a
percentage of Ki67-positive cells and represent the means ± standard error of 5–6 preparations. NS, not significant.
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and in confluent PMFs, but not during the period of cell
expansion in culture. In two independent studies of Collagen-
α1(I)-green fluorescent protein (Col1a1GFP) mice with induced
liver fibrosis, Fibulin 2, Thy-1 and elastin were overexpressed in
cells considered as activated portal fibroblasts (Iwaisako et al.,
2014; Lua et al., 2016). Consistent with RT-PCR analyses, dual
immunolabeling shows that after 3 days, most of the cells
are cytokeratin-negative (Figure 3Bb). Only a small number of
cytokeratin-positive cells localized in the apex of the cell clusters
are observed under confocal microscopy, whereas α-SMA is
expressed in cells that adhere to the substrate (Figure 3Bbb’b”).
Occasionally, a cytokeratin-positive cell adhering and migrating
on the substrate, can be seen at the periphery of the
cluster. However, we never detected co-expression of α-SMA
and cytokeratin in the same cell, providing evidence against
epithelial-mesenchymal transition in the emergence of PMF,
although this mechanism could not be formally excluded. After
4 days, virtually all the cells are α-SMA-positive, whereas
cytokeratin immunofluorescence is undetectable (Figure 3Bc).
Co-expression of α-SMA and COL15A1 can be detected,
although the intensity of COL15A1 immunofluorescence varies
between individual cells (Figure 3Bd).
The comparison of confluent PMFs after 4–5 days, in
primary culture (P0) and after one passage (P1), shows similar
characteristics. The mRNA levels of Vimentin, Acta2/α-SMA,
Col1a1, Col15a1, Fibulin 2, and CD90/Thy-1, are not significantly
different between PMFs at P0 and P1 (Figure 4A). The mRNA
levels of Elastin and Entpd2 are not significantly different between
P0 and P1 either (Data not shown), but too low to qualify
them as PMF markers. Compared to serum-free conditions or
primary rat hepatocytes, PMFs grown to confluence secrete
collagen abundantly, without significant difference between P0
and P1 (Figure 4B). PMFs are also highly proliferative in the
presence of serum, without significant difference between P0 and
P1 (Figure 4C).
In conclusion, the protocol that we herein describe, provides
a straightforward and reproducible method to obtain PMFs
in culture. There is strong evidence to indicate that the
progenitor cells giving rise to PMFs in vivo, are present in
the initial bile duct isolates. These cells proliferate intensely,
they acquire a fully differentiated myofibroblastic phenotype
in primary culture and maintain this phenotype after one
passage.
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